The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Targeting GRB7/ERK/FOXM1 Signaling Pathway Impairs Aggressiveness of Ovarian Cancer Cells
Open accessAbstract
Ovarian cancer is a highly lethal disease with poor prognosis and especially in high-grade tumor. Emerging evidence has reported that aberrant upregulation and activation of GRB7, ERK as well as FOXM1 are closely associated with aggresivenesss of human cancers. However, the interplay between these factors in the pathogenesis of human cancers still remains unclear. In this study, we found that GRB7 (P<0.0001), ERK phosphorylation (P<0.0001) and FOXM1 (P = 0.001) were frequently increased and associated with high-grade tumors, as well as a high tendency in association with advanced stage ovarian cancer by immunohistochemical analysis. Intriguingly, the expressions of GRB7 (P<0.0001), ERK phosphorylation (P<0.001) and FOXM1 (P<0.001) showed a significant stepwise increase pattern along Grade 1 to Grade 3 ovarian cancers. Biochemical studies using western blot analysis demonstrated that enforced expression or knockdown of GRB7 showed GRB7 could elevate the levels of ERK phosphorylation and FOXM1, whereas enforced expression of FOXM1 could not alter levels of GRB7 and ERK phosphorylation. But inhibition of ERK signaling by U0126 or PD98059 could reduce the level of FOXM1 in GRB7-overexpressing ovarian cancer cells, suggesting that GRB7, ERK and FOXM1 are regulated orderly. Moreover, inhibition of ERK activity by U0126 or PD98059, or decreased FOXM1 expression by Thiostrepton significantly inhibited cell migration/invasion, tumor growth in vitro and in vivo. Collectively, our findings confer that targeting GRB7/ERK/FOXM1 signaling cascade may be a promising molecular therapeutic choice in combating ovarian cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“GRB7 targeting inhibits ovarian cancer tumor growth through the ERK inhibition [36].”
From Genome-wide CRISPR-cas9 knockout screening identifies GRB7 as a driver for MEK inhibitor resistance in KRAS mutant colon cancer (2022) · cites this paper as [36]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mebratu, Y., & Tesfaigzi, Y. (2009) · Cell Cycle · doi:10.4161/cc.8.8.8147 · Cited by 957 · cited 1×
“Constitutive activation of ERK signaling pathway has been involved in human cancer development [30,31,32].”
BackgroundGrading Ovarian Serous Carcinoma Using a Two-Tier System
Malpica, A., Deavers, M. T., Lu, K., Bodurka, D. C., Atkinson, E. N., Gershenson, D. M., & Silva, E. G. (2004) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200404000-00009 · Cited by 670 · cited 1×
“nuclei, a high mitotic index, more aggressiveness, poorly differentiated, less responsive to chemotherapy as well as low survival rate [4,5,6].”
BackgroundVang, R., Shih, I.-M., & Kurman, R. J. (2009) · Advances in Anatomic Pathology · doi:10.1097/pap.0b013e3181b4fffa · Cited by 562 · cited 3×
“Ovarian cancer is a heterogeneous tumor exhibiting a wide range of cytological, clinical and altered genetic features [3,4].”
BackgroundSteelman, L. S., Chappell, W. H., Abrams, S. L., Kempf, C. R., Long, J., Laidler, P., Mijatovic, S., Maksimovic-Ivanic, D., Stivala, F., Mazzarino, M. C., et al. (2011) · Aging · doi:10.18632/aging.100296 · Cited by 553 · cited 1×
“Constitutive activation of ERK signaling pathway has been involved in human cancer development [30,31,32].”
BackgroundTargeting the RAF–MEK–ERK pathway in cancer therapy
Montagut, C., & Settleman, J. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.01.022 · Cited by 468 · cited 2×
“Besides, constitutive activation of ERK has been implicated in a variety of tumorigenic behaviors such as cell proliferation, differentiation, metastasis, angiogenesis, and chemoresistance in human cancers [13,14,15,16].”
BackgroundTargeting the ERK signaling pathway in cancer therapy
Kohno, M., & Pouyssegur, J. (2006) · Annals of Medicine · doi:10.1080/07853890600551037 · Cited by 416 · cited 1×
“Besides, constitutive activation of ERK has been implicated in a variety of tumorigenic behaviors such as cell proliferation, differentiation, metastasis, angiogenesis, and chemoresistance in human cancers [13,14,15,16].”
BackgroundFOXM1: From cancer initiation to progression and treatment
Koo, C.-Y., Muir, K. W., & Lam, E. W.-F. (2012) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2011.09.004 · Cited by 406 · cited 1×
“On the other aspect, emerging evidences have found that the aberrant upregulation of FOXM1 transcription factor is involved in the pathogenesis of various human cancers [17,21,22,38,39].”
BackgroundFOXM1, a typical proliferation-associated transcription factor
Wierstra, I., & Alves, J. (2007) · bchm · doi:10.1515/bc.2007.159 · Cited by 313 · cited 1×
“In addition, Forkhead Box M1 (FOXM1) has been identified as an oncogenic transcription factor which is frequently upregulated in numerous human cancers [17,18,19].”
BackgroundFoxM1: A Master Regulator of Tumor Metastasis
Raychaudhuri, P., & Park, H. J. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0640 · Cited by 308 · cited 3×
“In addition, Forkhead Box M1 (FOXM1) has been identified as an oncogenic transcription factor which is frequently upregulated in numerous human cancers [17,18,19].”
BackgroundOvarian Cancer Pathogenesis: A Model in Evolution
Karst, A. M., & Drapkin, R. (2010) · Journal of Oncology · doi:10.1155/2010/932371 · Cited by 298 · cited 1×
“Ovarian cancer is a heterogeneous tumor exhibiting a wide range of cytological, clinical and altered genetic features [3,4].”
BackgroundBristow, R. E., Palis, B. E., Chi, D. S., & Cliby, W. A. (2010) · Gynecologic Oncology · doi:10.1016/j.ygyno.2010.05.025 · Cited by 225 · cited 1×
“Ovarian cancer is the most lethal disease among all gynecological malignancies [1,2].”
BackgroundChan, D. W., Liu, V. W. S., Tsao, G. S. W., Yao, K.-M., Furukawa, T., Chan, K. K. L., & Ngan, H. Y. S. (2008) · Carcinogenesis · doi:10.1093/carcin/bgn167 · Cited by 215 · cited 2×
“Besides, constitutive activation of ERK has been implicated in a variety of tumorigenic behaviors such as cell proliferation, differentiation, metastasis, angiogenesis, and chemoresistance in human cancers [13,14,15,16].”
BackgroundSelf-citationHan, D. C., Shen, T.-L., & Guan, J.-L. (2001) · Oncogene · doi:10.1038/sj.onc.1204775 · Cited by 170 · cited 1×
“GRB7 is a known adaptor which relays signals from cell surface receptors to specific downstream signaling cascades via the protein-protein interaction of its Src-homology 2 (SH2) domain to a variety of tyrosine kinases [7,40,41].”
BackgroundO'Neill, C. J., Deavers, M. T., Malpica, A., Foster, H., & McCluggage, W. G. (2005) · American Journal of Surgical Pathology · doi:10.1097/01.pas.0000166367.68459.7d · Cited by 164 · cited 1×
“nuclei, a high mitotic index, more aggressiveness, poorly differentiated, less responsive to chemotherapy as well as low survival rate [4,5,6].”
BackgroundForkhead box M1 transcription factor: A novel target for cancer therapy
Wang, Z. P., Ahmad, A., Li, Y., Banerjee, S., Kong, D., & Sarkar, F. H. (2009) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2009.11.006 · Cited by 148 · cited 1×
“In addition, Forkhead Box M1 (FOXM1) has been identified as an oncogenic transcription factor which is frequently upregulated in numerous human cancers [17,18,19].”
BackgroundChan, D. W., Yu, S., Chiu, P., Yao, K., Liu, V., Cheung, A., & Ngan, H. (2008) · The Journal of Pathology · doi:10.1002/path.2355 · Cited by 134 · cited 2×
“We and others have recently found that the upregulation of FOXM1 enhances cell proliferation, migration/invasion and particularly its expression is involved in cancer progression [17,20,21,22].”
BackgroundSelf-citationThe Grb7 Family of Signalling Proteins
Daly, R. J. (1998) · Cellular Signalling · doi:10.1016/s0898-6568(98)00022-9 · Cited by 116 · cited 2×
“Growth factor receptor-bound protein 7 (GRB7) is a signaling adaptor which functions to couple signals from cell surface receptors to specific signaling pathways [7].”
BackgroundSignaling Through RAS-RAF-MEK-ERK: from Basics to Bedside
Zebisch, A., Czernilofsky, A. P., Kéri, G., Smigelskaite, J., Sill, H., & Troppmair, J. (2007) · Current Medicinal Chemistry · doi:10.2174/092986707780059670 · Cited by 112 · cited 1×
“Constitutive activation of ERK signaling pathway has been involved in human cancer development [30,31,32].”
BackgroundTargeting Ras-RAF-ERK and its Interactive Pathways as a Novel Therapy for Malignant Gliomas
Lo, H. (2010) · Current Cancer Drug Targets · doi:10.2174/156800910793357970 · Cited by 102 · cited 1×
“Indeed, targeting this pathway to combat human cancers has been attracted plenty of effort to develop effective drugs for the past decade [15,33,34,35].”
BackgroundTanaka, S., Mori, M., Akiyoshi, T., Tanaka, Y., Mafune, K., Wands, J. R., & Sugimachi, K. (1997) · PubMed · Cited by 91
Identification of Novel Non-phosphorylated Ligands, Which Bind Selectively to the SH2 Domain of Grb7
Pero, S. C., Oligino, L., Daly, R. J., Soden, A. L., Liu, C., Roller, P. P., Li, P., & Krag, D. N. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m111816200 · Cited by 90 · cited 2×
“However, the specificity and affinity are the main hurdles encountered in the development of these inhibitors as GRB7-targeted molecular therapeutics [26,49,50].”
BackgroundMicroenvironment and Pathogenesis of Epithelial Ovarian Cancer
Saad, A. F., Hu, W., & Sood, A. K. (2010) · Hormones and Cancer · doi:10.1007/s12672-010-0054-2 · Cited by 88 · cited 1×
“It has been documented that high-grade ovarian tumor exhibits high capacity in cell migration/invasion [4,24].”
BackgroundSpecific Peptide Ligand for Grb7 Signal Transduction Protein and Pancreatic Cancer Metastasis
Tanaka, S., Pero, S. C., Taguchi, K., Shimada, M., Mori, M., Krag, D. N., & Arii, S. (2006) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djj105 · Cited by 86 · cited 2×
“For examples, the combination of Grb7 cyclic peptide, G7-18NATE, with chemo-drugs were capable of inhibiting breast cancer cell growth [47,48], or with the specific peptide ligand to suppress GRB7-mediated metastasis in pancreatic carcinoma etc [11,49].”
BackgroundThe Ras‐ERK pathway: Understanding site‐specific signaling provides hope of new anti‐tumor therapies
Calvo, F., Agudo‐Ibáñez, L., & Crespo, P. (2010) · BioEssays · doi:10.1002/bies.200900155 · Cited by 85 · cited 1×
“Besides, constitutive activation of ERK has been implicated in a variety of tumorigenic behaviors such as cell proliferation, differentiation, metastasis, angiogenesis, and chemoresistance in human cancers [13,14,15,16].”
BackgroundRNAi-mediated ERK2 knockdown inhibits growth of tumor cells in vitro and in vivo
Bessard, A., Frémin, C., Ezan, F., Fautrel, A., Gailhouste, L., & Baffet, G. (2008) · Oncogene · doi:10.1038/onc.2008.163 · Cited by 81
Grb7 is a Downstream Signaling Component of Platelet-derived Growth Factor α- and β-Receptors
Yokote, K., Margolis, B. L., Heldin, C., & Claesson, L. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.48.30942 · Cited by 81 · cited 1×
“GRB7 is a known adaptor which relays signals from cell surface receptors to specific downstream signaling cascades via the protein-protein interaction of its Src-homology 2 (SH2) domain to a variety of tyrosine kinases [7,40,41].”
BackgroundLok, G. T. M., Chan, D. W., Liu, V. W. S., Hui, W. W. Y., Leung, T. H. Y., Yao, K., & Ngan, H. (2011) · PLoS ONE · doi:10.1371/journal.pone.0023790 · Cited by 78 · cited 6×
“By immunohistochemical (IHC) analysis on an ovarian cancer tissue array (OVC1021), we found that all of these factors were congruently upregulated in ovarian cancer samples which was consistent with our previous findings [12,21].”
BackgroundResultSelf-citationPriller, M., Pöschl, J., Abrão, L., von Bueren, A. O., Cho, Y., Rutkowski, S., Kretzschmar, H. A., & Schüller, U. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1214 · Cited by 77 · cited 1×
“Indeed, previous publications reported that knockdown of FOXM1 and ERK could reduce cell growth and invasiveness of human cancers [27,28,29].”
BackgroundPero, S. C., Shukla, G. S., Cookson, M. M., Flemer, S., & Krag, D. N. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603732 · Cited by 69 · cited 1×
“For examples, the combination of Grb7 cyclic peptide, G7-18NATE, with chemo-drugs were capable of inhibiting breast cancer cell growth [47,48], or with the specific peptide ligand to suppress GRB7-mediated metastasis in pancreatic carcinoma etc [11,49].”
BackgroundMcCubrey, J. A., Steelman, L. S., Abrams, S. L., Chappell, W. H., Russo, S. M., Ove, R., Milella, M., Tafuri, A., Lunghi, P., Bonati, A., et al. (2010) · Expert Opinion on Emerging Drugs · doi:10.1517/14728210903282760 · Cited by 63 · cited 1×
“Indeed, targeting this pathway to combat human cancers has been attracted plenty of effort to develop effective drugs for the past decade [15,33,34,35].”
BackgroundGRB-7 facilitates HER-2/Neu-mediated signal transduction and tumor formation
Bai, T., & Luoh, S. (2007) · Carcinogenesis · doi:10.1093/carcin/bgm221 · Cited by 63 · cited 1×
“We and others have previously reported that GRB7 is frequently overexpressed and promotes cell proliferation, cell migration and cell invasion of human cancers [10,12,42].”
BackgroundWu, Q., Liu, C., Tai, M., Liu, D., Lei, L., Wang, R., Tian, M., & Lü, Y. (2010) · Acta Pharmacologica Sinica · doi:10.1038/aps.2010.4 · Cited by 60 · cited 1×
“Indeed, previous publications reported that knockdown of FOXM1 and ERK could reduce cell growth and invasiveness of human cancers [27,28,29].”
BackgroundGRB7 is required for triple-negative breast cancer cell invasion and survival
Giricz, O., Calvo, V., Pero, S. C., Krag, D. N., Sparano, J. A., & Kenny, P. A. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1822-6 · Cited by 58 · cited 1×
“We and others have recently found that GRB7 and its variant, GRB7v, are frequently upregulated in ovarian cancers and are able to enhance cell proliferation, migration/invasion through activating ERK signaling pathway [12,36,37].”
BackgroundGrb7 signal transduction protein mediates metastatic progression of esophageal carcinoma
Tanaka, S., Sugimachi, K., Kawaguchi, H., Saeki, H., Ohno, S., Wands, J. R., & Sugimachi, K. (2000) · Journal of Cellular Physiology · doi:10.1002/(sici)1097-4652(200006)183:3<411::aid-jcp14>3.0.co;2-z · Cited by 55 · cited 2×
“We and others have previously reported that GRB7 is frequently overexpressed and promotes cell proliferation, cell migration and cell invasion of human cancers [10,12,42].”
BackgroundFocal Adhesion Kinase Controls Aggressive Phenotype of Androgen-Independent Prostate Cancer
Johnson, T. R., Khandrika, L., Kumar, B., Venezia, S., Koul, S., Chandhoke, R. A., MARONI, P. D., Donohue, R. E., Meacham, R. B., & Koul, H. K. (2008) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-08-0052 · Cited by 50 · cited 1×
“Indeed, previous publications reported that knockdown of FOXM1 and ERK could reduce cell growth and invasiveness of human cancers [27,28,29].”
BackgroundGRB7 protein over-expression and clinical outcome in breast cancer
Ramsey, B., Bai, T., Newell, A. H., Troxell, M. L., Park, B. S., Olson, S. B., Keenan, E. J., & Luoh, S. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1010-0 · Cited by 50 · cited 1×
“We and others have recently found that GRB7 and its variant, GRB7v, are frequently upregulated in ovarian cancers and are able to enhance cell proliferation, migration/invasion through activating ERK signaling pathway [12,36,37].”
BackgroundPorter, C. J., Matthews, J. M., Mackay, J. P., Pursglove, S. E., Schmidberger, J. W., Leedman, P. J., Pero, S. C., Krag, D. N., Wilce, M. C., & Wilce, M. C. J. (2007) · BMC Structural Biology · doi:10.1186/1472-6807-7-58 · Cited by 44 · cited 1×
“Given to its important roles as signal transduction molecules in activating oncogenic signaling pathways, numerous studies have attempted to develop inhibitors targeting to the SH2 domain of GRB7 in order to inhibiting aberrant activation of related signaling activities and eliminating cancer cells [43,44,45,46].”
BackgroundWalch, A. K., Specht, K., Braselmann, H., Stein, H. J., Siewert, J. R., Hopt, U. T., Höfler, H., & Werner, M. (2004) · International Journal of Cancer · doi:10.1002/ijc.20411 · Cited by 44 · cited 2×
“Emerging evidences have reported that GRB7 is overexpressed and usually accompanied with overexpression of erbB2 in human cancers [8,9].”
BackgroundGrb7-based molecular therapeutics in cancer
Pero, S. C., Daly, R. J., & Krag, D. N. (2003) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399403006227 · Cited by 43 · cited 2×
“However, the specificity and affinity are the main hurdles encountered in the development of these inhibitors as GRB7-targeted molecular therapeutics [26,49,50].”
BackgroundWang, Y., Chan, D. W., Liu, V. W. S., Chiu, P., & Ngan, H. Y. S. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0018 · Cited by 41 · cited 9×
“of Obstetrics & Gynaecology, University of Ottawa) [23], and OVCA433 (obtained from American Type Culture Collection, Rockville, MD), as well as two GRB7 stably expressing clones; C19 in OVCA433 and C15 in A2780cp which were generated previously [12] were included in this study.”
BackgroundMethodResultSelf-citationMEK inhibitors: a patent review 2008 – 2010
Trujillo, J. I. (2011) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2011.577068 · Cited by 40 · cited 1×
“Indeed, targeting this pathway to combat human cancers has been attracted plenty of effort to develop effective drugs for the past decade [15,33,34,35].”
BackgroundSchneiderman, D., Kim, J.-M., Senterman, M., & Tsang, B. K. (1999) · APOPTOSIS · doi:10.1023/a:1026456926754 · Cited by 40
Wang, Z., Wang, M., & Carr, B. I. (2000) · Journal of Cellular Physiology · doi:10.1002/(sici)1097-4652(200006)183:3<381::aid-jcp11>3.0.co;2-o · Cited by 27
Benzopyrazine derivatives: A novel class of growth factor receptor bound protein 7 antagonists
Ambaye, N. D., Gunzburg, M. J., Lim, R. C. C., Price, J. T., Wilce, M. C. J., & Wilce, M. C. J. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.10.030 · Cited by 23 · cited 1×
“Given to its important roles as signal transduction molecules in activating oncogenic signaling pathways, numerous studies have attempted to develop inhibitors targeting to the SH2 domain of GRB7 in order to inhibiting aberrant activation of related signaling activities and eliminating cancer cells [43,44,45,46].”
BackgroundAmbaye, N. D., Pero, S. C., Gunzburg, M. J., Yap, M., Clayton, D., Borgo, M. P. D., Perlmutter, P., Aguilar, M., Shukla, G. S., Peletskaya, E. N., et al. (2011) · Journal of Molecular Biology · doi:10.1016/j.jmb.2011.07.030 · Cited by 22 · cited 1×
“Given to its important roles as signal transduction molecules in activating oncogenic signaling pathways, numerous studies have attempted to develop inhibitors targeting to the SH2 domain of GRB7 in order to inhibiting aberrant activation of related signaling activities and eliminating cancer cells [43,44,45,46].”
BackgroundGunzburg, M. J., Ambaye, N. D., Borgo, M. P. D., Pero, S. C., Krag, D. N., Wilce, M. C. J., & Wilce, J. A. (2011) · Journal of Molecular Recognition · doi:10.1002/jmr.2148 · Cited by 17 · cited 1×
“For examples, the combination of Grb7 cyclic peptide, G7-18NATE, with chemo-drugs were capable of inhibiting breast cancer cell growth [47,48], or with the specific peptide ligand to suppress GRB7-mediated metastasis in pancreatic carcinoma etc [11,49].”
BackgroundNMR analysis of G7‐18NATE, a nonphosphorylated cyclic peptide inhibitor of the Grb7 adapter protein
Porter, C. J. H., & Wilce, M. C. J. (2007) · Biopolymers · doi:10.1002/bip.20667 · Cited by 15 · cited 1×
“However, the specificity and affinity are the main hurdles encountered in the development of these inhibitors as GRB7-targeted molecular therapeutics [26,49,50].”
BackgroundD'Alò, D., Stracci, F., Cassetti, T., Scheibel, M., Pascucci, C., & Rosa, F. L. (2010) · PubMed · Cited by 9
Zhang, D., Shao, C., Hu, S., Ma, S., & Gao, Y. (2012) · PLoS ONE · doi:10.1371/journal.pone.0029902 · Cited by 8 · cited 1×
“Given to its important roles as signal transduction molecules in activating oncogenic signaling pathways, numerous studies have attempted to develop inhibitors targeting to the SH2 domain of GRB7 in order to inhibiting aberrant activation of related signaling activities and eliminating cancer cells [43,44,45,46].”
Background[Ovarian carcinomas. Intraperitoneal chemotherapy by needle].
Zylberberg, B., Dormont, D., Jh, R., Madélénat, P., Salat‐Baroux, J., Ferrand, G., Antoine, J.-M., & Pennehouat, G. (1991) · PubMed · Cited by 3
Giricz, O., Calvo, V., Pero, S. C., Krag, D. N., Sparano, J. A., & Kenny, P. A. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.targ-11-c156 · Cited by 1
Research works printed but not linked: 1
- CY Koo, 2012, FOXM1: From cancer initiation to progression and treatment, Biochim Biophys Acta, 1819, 28, 10.1016/j.bbagrm.2011.09.004 · DOI · Paper page
Cited by
FOXM1 (Forkhead box M1) in Tumorigenesis
(2013) · Advances in Cancer Research · doi:10.1016/b978-0-12-407190-2.00016-2 · Cited by 184
“In particular, the FOXM1 expression level increases with tumor grade or stage (Carr et al., 2012; Chan et al., 2008, 2012; Chen et al., 2013b; Chu et al., 2012; He et al., 2012; Janus et al., 2011; Jiang et al., 2011; Kalin et al., 2006; Laurendeau et al., 2010; Li et al., 2012a, 2013; Lin et…”
BackgroundThe Transcription Factor FOXM1 (Forkhead box M1)
(2013) · Advances in Cancer Research · doi:10.1016/b978-0-12-407173-5.00004-2 · Cited by 176
FOXM1 and Cancer: Faulty Cellular Signaling Derails Homeostasis
Kalathil, D., John, S., & Nair, A. S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.626836 · Cited by 168
FoxM1: Repurposing an oncogene as a biomarker
Nandi, D., Cheema, P. S., Jaiswal, N., & Nag, A. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.08.009 · Cited by 148
Activation of AMPK inhibits cervical cancer cell growth through AKT/FOXO3a/FOXM1 signaling cascade
Yung, M. M. H., Chan, D. W., Liu, V. W. S., Yao, K., & Ngan, H. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-327 · Cited by 112
“impairs tumor growth of this cancer in vitro and in vivo [18,25,27,33], suggesting that targeting FOXM1 is an appealing and potential approach for anticancer therapeutics.”
BackgroundSelf-citation
Metadata
- Authors
- Chan, D. W., Hui, W. W. Y., Cai, P. C. H., Liu, M. X., Yung, M. M. H., Mak, C. S. L., Leung, T. H. Y., Chan, K. K. L., & Ngan, H. Y. S.
- Affiliations
- University of Hong Kong (HK)
- Corresponding author
- Chan, David W.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2012-12-20
- Volume
- 7
- Issue
- 12
- Pages
- e52578
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3527599
- OpenAlex
- W2000095065
- Cited by
- 51
- References
- 50
- Citations by year
- 2026: 1 · 2024: 2 · 2023: 3 · 2022: 1 · 2021: 6 · 2020: 7 · 2019: 2 · 2018: 1 · 2017: 8 · 2016: 3 · 2015: 6 · 2014: 5 · 2013: 6
- FWCI
- 6.35
- Type
- journal article
- Language
- en
- Update notices
- correction (2014-10-06)
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- The HKU Scholars Hub (University of Hong Kong) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Keywords
- ovarian cancer, Grb7, ERK1/2 phosphorylation, FOXM1, tumor aggressiveness, tumor grade, cell migration and invasion, tumor growth, ERK inhibition, thiostrepton, U0126, PD98059, molecular therapy
- MeSH terms
- Forkhead Box Protein M1, Animals, Cell Movement, Female, Humans, Mice, Inbred BALB C, Neoplasm Invasiveness, Ovarian Neoplasms, Phosphorylation, Signal Transduction, Xenograft Model Antitumor Assays, Cell Line, Tumor, Extracellular Signal-Regulated MAP Kinases, Cell Proliferation, Mice, GRB7 Adaptor Protein, Forkhead Transcription Factors, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.